Profile - To The Moon

Petronovic

Posts · 0Posts · 0
Following · 0Following · 0
Followers · 0Followers · 0

- PetronovicPetronovic
  ·2025-08-23
  Great article, would you like to share it?
  Sorry, this post has been deleted
  991 Comment
  1
  Share
  Report
- PetronovicPetronovic
  ·2025-06-11
  Looks to have merit but presumably expensive to get unless listed on PBS.
  Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis
  Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology Congress in Barcelona, Spain, from June 11-14, 2025.Disclaimer: This news brief was created by Public Technologies using generative artificial intelligence. While PUBT strives to provide accurate and timely informati
  Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis
  1.19K Comment
  1
  Share
  Report
- PetronovicPetronovic
  ·2025-04-22
  The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh
  Sorry, this post has been deleted
  1.62K Comment
  3
  Share
  Report
No followers yet

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4145104526174422","uuid":"4145104526174422","gmtCreate":1682002565520,"gmtModify":1682512383681,"name":"Petronovic","pinyin":"petronovic","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":105,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":4,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.01.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-1","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Experiencer","description":"5 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://community-static.tradeup.com/news/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006}],"userBadgeCount":2,"currentWearingBadge":{"badgeId":"cbe1c45c584340f3bd9ae6c77e0e9981-1","templateUuid":"cbe1c45c584340f3bd9ae6c77e0e9981","name":"Academy Experiencer","description":"5 lessons learned","bigImgUrl":"https://community-static.tradeup.com/news/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://community-static.tradeup.com/news/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":8,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":470612131315960,"gmtCreate":1755932920631,"gmtModify":1755934514027,"author":{"id":"4145104526174422","authorId":"4145104526174422","name":"Petronovic","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4145104526174422","idStr":"4145104526174422"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/470612131315960","repostId":"2561340272","repostType":2,"isVote":1,"tweetType":1,"viewCount":991,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":444948927574240,"gmtCreate":1749648629323,"gmtModify":1749648661880,"author":{"id":"4145104526174422","authorId":"4145104526174422","name":"Petronovic","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4145104526174422","idStr":"4145104526174422"},"themes":[],"htmlText":"Looks to have merit but presumably&nbsp; expensive to get unless listed on PBS.","listText":"Looks to have merit but presumably&nbsp; expensive to get unless listed on PBS.","text":"Looks to have merit but presumably expensive to get unless listed on PBS.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/444948927574240","repostId":"2542852885","repostType":2,"repost":{"id":"2542852885","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1749639568,"share":"https://ttm.financial/m/news/2542852885?lang=en_US&edition=fundamental","pubTime":"2025-06-11 18:59","market":"us","language":"en","title":"Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2542852885","media":"Reuters","summary":"Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu  in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology  Congress in Barcelona, Spain, from June 11-14, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informati","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, from June 11-14, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610213248) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-11 18:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, from June 11-14, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610213248) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4534":"瑞士信贷持仓","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BMY":"施贵宝","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4588":"碎股","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","BK4007":"制药","LU0237698245.USD":"富达环球地产基金A","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4585":"ETF&股票定投概念","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL5PQk2s:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2542852885","content_text":"Bristol Myers Squibb Announces Positive Phase 3 Trial Results for Sotyktu in Treating Psoriatic Arthritis\n    \n\n        Bristol Myers Squibb Company has announced positive results from the pivotal Phase 3 POETYK PsA-1 trial evaluating the efficacy and safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis. The study demonstrated that significantly more patients treated with Sotyktu achieved improvements in joint and skin symptoms, as well as in measures of disease activity and quality of life by Week 16. Additionally, new data from the POETYK PsA-2 trial indicated that clinical responses continued to improve and outcomes were maintained through Week 52. Sotyktu was well tolerated and demonstrated a safety profile consistent with previous studies. The results from the POETYK PsA-1 trial are being presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, from June 11-14, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20250610213248) on June 11, 2025, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{"BMY":0.9}},"isVote":1,"tweetType":1,"viewCount":1190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":427114298618056,"gmtCreate":1745296664519,"gmtModify":1745296989390,"author":{"id":"4145104526174422","authorId":"4145104526174422","name":"Petronovic","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4145104526174422","idStr":"4145104526174422"},"themes":[],"htmlText":"The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh","listText":"The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh","text":"The chart is obviously wrong presumably an AI glitch. It seems that Motley Fool is not even cursorily checking what they put out there in their name. Peter Cavanagh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/427114298618056","repostId":"2529087472","repostType":2,"isVote":1,"tweetType":1,"viewCount":1624,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}